The High Price of 'Free' Trade: U.S. Trade Agreements and Access to Medicines

Lopert, Ruth; Gleeson, Deborah
March 2013
Journal of Law, Medicine & Ethics;Spring2013, Vol. 41 Issue 1, p199
Academic Journal
The United States' pursuit of increasingly TRIPS-Plus levels of intellectual property protection for medicines in bilateral and regional trade agreements is well recognized. Less so, however, are U.S. efforts through these agreements to influence and constrain the pharmaceutical coverage programs of its trading partners. Although arguably unsuccessful in the Australia- U.S. Free Trade Agreement (AUSFTA), the U.S. nevertheless succeeded in its bilateral FTA with South Korea (KORUS) in establishing prescriptive provisions pertaining to the operation of coverage and reimbursement programs for medicines and medical devices, which have the potential to adversely impact future access in that country. More recently, draft texts leaked from the current Trans Pacific Partnership Agreement (TPPA) negotiations show that U.S. objectives include not only AUSFTA-Plus and KORUS-Plus IP provisions but also ambitious inroads into the domestic health programs of its TPPA partners. This highlights the apparent conflict between trade goals - pursued through multilateral legal instruments to promote economic 'health'- and public health objectives, such as the development of treatments for neglected diseases, the pursuit of efficiency and equity in priority setting, and the procurement of medicines at prices that reflect their therapeutic value and facilitate affordable access.


Related Articles

  • Presidential Messaging, Innovation, and Intellectual Property. DAMES, K. MATTHEW // Information Today;Apr2011, Vol. 28 Issue 4, p24 

    The article examines U.S. President Barack Obama's 2011 State of the Union address on January 25, 2011, stressing the role of American innovation and creativity to U.S. economy and the necessity of protecting its intellectual property (IP). It mentions organizations like the General Agreement on...

  • Pending Patent Bill Puts. Edwards Jr., James R. // Human Events;4/25/2011, Vol. 67 Issue 16, p20 

    The article focuses on the proposed reform of the patent law that will benefit multinational companies and to promote harmonization in the U.S. It discusses the disadvantage of the reform to holders of intellectual property rights and to the economy of a country that is considered the global...

  • Patent Reform Adds Value to Biotech's Intellectual Property.  // Bioworld Week;3/14/2011, Vol. 19 Issue 11, p4 

    The article offers information on the America Invents Act, S. 23, a patent reform bill in the U.S. that inhibits diversion of patent fees to other government programs.

  • Intellectual property law in Israel, and US and European objections: Market exclusivity vs. data exclusivity. Morag-Sela, Tamar; Cohn, Ilan; Kowalski, Thomas J.; Jarecki-Black, Judy; Clyde-Watson, Zoe // Nature Biotechnology;Dec2004, Vol. 22 Issue 12, p1591 

    The article discusses issues related to intellectual property (IP) rights to pharmaceuticals in Israel. The country has a very strong generic pharmaceutical industry. Israel's past record of defending and respecting IP rights has led major companies around the world to file patent applications...

  • Pharmaceutical Companies and Global Lack of Access to Medicines: Strengthening Accountability under the Right to Health. Grover, Anand; Citro, Brian; Mankad, Mihir; Lander, Fiona // Journal of Law, Medicine & Ethics;Summer2012, Vol. 40 Issue 2, p234 

    Many medicines currently available on the market are simply too expensive for millions around the world to afford. Many medicines available in the developing world are only available to a small percentage of the population due to economic inequities. The profit-seeking behavior of pharmaceutical...

  • Patenting the Curve Ball: Business Methods and Industry Norms. Magliocca, Gerard N. // Brigham Young University Law Review;2009, Vol. 2009 Issue 4, p875 

    The article discusses the idea that patents should be given subject to the norms of a relevant industry. The author cites the example that if the inventor of the curve ball would be granted a patent, the game of baseball will suffer caused by the granting of undue advantage to the patent owner....

  • The Role and Challenges of IP in Times of Corporate Reinvention. Nakamura, Jun; Suzuki, Toshiaki // Landslide;Nov/Dec2011, Vol. 4 Issue 2, p18 

    The article discusses the role and challenges of intellectual property protection in the U.S. It is said that the business press highlights attributes of companies that emerge from downturns as healthier and more viable companies, as the global economy emerges from a depression. Fujifilm's name...

  • LICENSING RESTRICTIONS ON FIELDS OF USE VS. ADJACENT MARKETS: A POTENTIAL ECONOMIC BASIS FOR DIFFERENT LEGAL TREATMENT. Schwartz, Marius // New York University Annual Survey of American Law;2011, Vol. 66 Issue 3, p435 

    In this article the author reflects on the field-of-use against adjacent markets restrictions on intellectual property (IP) licensing in the U.S. The author cites the different legal treatment and cost and benefits in field-of-use restrictions and adjacent market restrictions. The author states...

  • Protecting your client's intellectual property. Gonce, J. David // Tennessee Bar Journal;Oct2006, Vol. 42 Issue 10, p14 

    The article provides a brief overview of various forms of intellectual property protection available under federal and state law, the subject matter that they are designed to cover and some of the advantages and disadvantages of pursuing one form of intellectual property protection. The three...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics